A genetic variant associated with aggressive prostate cancer has been discovered by researchers at Wake Forest University Baptist Medical Center. Claiming their discovery as a “first,” the scientists say that one day genetic information may be used in combination with other factors to guide treatment decisions.
Why do some men with elevated prostate specific antigen (PSA) levels who are carefully monitored and undergo repeated negative biopsies still develop aggressive prostate cancer? Clinical researchers at Princess Margaret Hospital (PMH) in Toronto, Canada believe they can now answer that baffling question.
Measuring velocity of prostate cancer specific antigen rise over time may not be necessary before deciding whether a man needs a prostate biopsy, according to a large new study from urologists at US and European cancer centers.
PSA velocity (PSAV) is a term used for change PSA levels in the blood over time. Instead of basing a decision to recommend biopsy (or not) on a single annual PSA reading, the urologist looks at a series of tests and calculates the rate of rise over time.
The new study suggests that calculating PSA velocity does not help to detect prostate cancer once PSA and age are taken into consideration.
This finding was reported by European Association of Urolog this August. “Some guidelines,” Scardino notes, “do incorporate PSAV cut points as an indication for biopsy.”